Researchers discovered a regulatory element controlling gene Cdx2's function, crucial for embryonic and extraembryonic cell lineages. This finding helps understand early specification of trophectoderm, essential for mammalian development.
Researchers have identified a new therapeutic target for certain myeloproliferative diseases by targeting the microenvironment that sustains hematopoietic stem cells. The treatment involves using clinically approved medications to prevent or reverse damage to this microenvironment.
Researchers at CNIC and CNIO successfully reproduce chromosomal translocations in human cells, identical to those found in leukemia and sarcoma patients. This breakthrough enables the study of new therapeutic targets and therapies for cancer treatment.
Cells adjust mitochondrial apparatus to burn sugars or fats, adapting to changes in fuel supply. The study identifies signals and molecules that regulate this adaptation, enabling cells to switch between glucose and fatty acid burning more efficiently.
A new 6-month follow-up study confirms that early treatment with metoprolol significantly reduces dead heart muscle, hospital readmissions, and cardioverter-defibrillator implantation. The treatment also shows promise for reducing chronic heart failure cases.
A new study describes a mechanism by which microRNAs are encapsulated and exported in nanovesicles, facilitating intercellular communication. The researchers identified EXOmotifs, specific nucleotide sequence patterns, that enable the export of miRNAs from human T lymphocytes.
Researchers from CNIC and CSIC discover that inhibiting protein Rcan1 reduces burden of atherosclerosis in mice. Genetic inactivation of the protein represses disease development by favoring anti-inflammatory characteristics in macrophages.
The METOCARD-CNIC study found that metoprolol significantly reduces infarct size and improves heart contractility. The treatment's cost-effectiveness is estimated to save thousands of euros per patient over time.
A study led by Dr. Luca Scorrano and Dr. José Antonio Enríquez found that the OPA1 gene can regulate cellular metabolism, potentially leading to new treatments for mitochondrial diseases. The researchers discovered that increasing OPA1 activity enhances energy production and cell growth.
Researchers discover cell competition in early embryo, where cells with higher Myc protein levels eliminate those with lower levels. This mechanism optimizes the development of long-lived organisms like humans by selecting suitable cells.
In early mammalian development, embryonic cells undergo a battle for survival between days 3 and 7. Cells with higher levels of Myc protein eliminate those with lower levels through an optimization mechanism. This study reveals that this process does not waste cellular resources but instead benefits the embryo.
Researchers confirm their 2008 model for mitochondrial function, which explains the symptoms of diseases and reveals the role of five molecular machines in converting energy. The study also highlights the dynamic nature of mitochondrial energy extraction, which can be optimized based on dietary composition.
CNIC researchers have identified a possible treatment to block the deposition of calcium in arterial walls, a key symptom of premature aging disease. Chronic treatment with pyrophosphate inhibits calcium deposition, which is accelerated in mice with Hutchinson-Gilford progeria syndrome.
Researchers discovered that discarded immune cells stimulate the release of hematopoietic stem cells from the bone marrow into the bloodstream. This process is regulated by the daily elimination of neutrophils and follows a circadian cycle, which could have implications for cardiovascular health.